AstraZeneca (AZN) has released an update.
AstraZeneca has completed its acquisition of Fusion Pharmaceuticals, enhancing its oncology portfolio with innovative radioconjugates (RCs) and strengthening its influence in Canada. The deal, valued at roughly $2.4 billion, includes an upfront cash payment and potential future payments tied to regulatory milestones. With Fusion now a wholly owned subsidiary, AstraZeneca bolsters its position in the fight against cancer, including promising treatments like FPI-2265 for metastatic castration-resistant prostate cancer.
For further insights into AZN stock, check out TipRanks’ Stock Analysis page.
